Black Diamond Therapeutics (BDTX) Return on Sales (2025)

Black Diamond Therapeutics (BDTX) posted Return on Sales of 0.0% for Q4 2025, up 17.95% on a QoQ basis from 0.0% in Q3 2025.

Black Diamond Therapeutics (BDTX) Return on Sales (2025) Analysis & Trends

Black Diamond Therapeutics' Return on Sales history runs 1 years deep, the most recent figure standing at 0.0% for Q4 2025.

Quarterly Return on Sales changed N/A year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed N/A YoY) and the FY2025 annual result came in at 0.02%, changed N/A from the prior year.
Return on Sales was 0.0% for Q4 2025 at Black Diamond Therapeutics, up from 0.0% in the prior quarter.
Across five years, Return on Sales topped out at 0.01% in Q1 2025 and bottomed at 0.0% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	0.00%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	0.00%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	0.00%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Black Diamond Therapeutics	99.59 Mn	-18.67 Mn	-	-

Download Data